Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 12 Lymphoma, Non-Hodgkin 7 Carcinoma, Non-Small-Cell Lung 5 Lymphoma, Large B-Cell, Diffuse 4 Breast Neoplasms 4 Recurrence 3 Melanoma 3 Lymphoma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Urinary Bladder Neoplasms 2 Lymphoma, Follicular 2 Cytokine Release Syndrome 2 Craniopharyngioma 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Sarcoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 52 Vincristine 32 blinatumomab 30 Prednisone 27 Methotrexate 27 Cytarabine 25 Dexamethasone 23 Specimen Handling 21 Rituximab 20 Doxorubicin 19 merphos 18 Mercaptopurine 18 Etoposide 18 fludarabine 17 Biopsy 17 prednylidene 16 deltacortene 16 N,N-dicyclohexyl-isoborneol-10-sulfonamide 16 Calcium Dobesilate 16 dexamethasone acetate 15 dexamethasone 21-phosphate 15 auricularum 15 Inotuzumab Ozogamicin 15 pegaspargase 14 azathiopurine 14 venetoclax 13 Asparaginase 13 Spinal Puncture 12 Leucovorin 12 CT-P10 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Burkitt Lymphoma × tocilizumab × 1 year × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡